Influence of Multidisciplinary Breast Tumor Board on Physician Decision

July 11, 2018 updated by: Murat Ferhat Ferhatoglu, Okan University

Influence of Multidisciplinary Breast Tutor Board on Physician Clinical Decision

In our study, the treatment plan for the case prior to the breast tumor counseling will be asked to physician and the treatment protocol observed by the primary physician will be observed after the decision of the tumor council.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

120

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

120 patients having breast cancer

Description

Inclusion Criteria:

Patients having primary breast cancer

Exclusion Criteria:

Patients having recurrent breast cancer -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group A
Patients treated according to suggestions of tumor board
Other: Breast cancer treatment
Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
Group B
Patients not treated according to suggestions of tumor board
Other: Breast cancer treatment
Multidisciplinary approach for breast cancer treatment is more beneficial for the patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Better survival
Time Frame: 2 years
Multidisciplinary approach creates better survival
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Okan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

August 13, 2018

Primary Completion (Anticipated)

August 13, 2019

Study Completion (Anticipated)

November 13, 2019

Study Registration Dates

First Submitted

July 11, 2018

First Submitted That Met QC Criteria

July 11, 2018

First Posted (Actual)

July 23, 2018

Study Record Updates

Last Update Posted (Actual)

July 23, 2018

Last Update Submitted That Met QC Criteria

July 11, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OkanU2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Breast cancer treatment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe